- |||||||||| Review, Journal, Metastases: Improving survival in metastatic colorectal cancer through optimized patient selection. (Pubmed Central) - May 28, 2024
Current treatment guidelines state that each therapy can be given before or after the others. Generally, sequencing considerations in the refractory setting include multiple variables such as tumor characteristics, toxicities, factors that are important to the patient, response to prior lines of therapy, and extent of disease.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase III, Journal: Use of biologics in Chinese pregnant patients with deficiency of interleukin-36 receptor antagonist (DITRA): A case series. (Pubmed Central) - May 28, 2024
Most pregnancy courses were uneventful, except for one woman who had recurrent episodes of decreased fetal heart rate variability after adalimumab injections, which subsided after switching to etanercept. The treatment effectiveness and safety demonstrated in our cases suggested the role of biologics for the treatment of IH in patients with DITRA.
- |||||||||| AVT03 (denosumab biosimilar) / Alvotech, Dr. Reddy's
Trial completion: AVT03 With Xgeva in Healthy Male Subjects (clinicaltrials.gov) - May 28, 2024
P1, N=208, Completed,
The treatment effectiveness and safety demonstrated in our cases suggested the role of biologics for the treatment of IH in patients with DITRA. Active, not recruiting --> Completed
- |||||||||| Krystexxa (pegloticase) / Amgen
Enrollment open, Trial completion date, Trial primary completion date: Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) - May 27, 2024
P4, N=10, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 | Active, not recruiting --> Recruiting
- |||||||||| Stivarga (regorafenib) / Bayer
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Regorafenib in patients with pretreated advanced melanoma: a single-center case series. (Pubmed Central) - May 27, 2024
REGO has a manageable safety profile in advanced melanoma patients, in monotherapy as well as combined with BRAF/MEK inhibitors or PD-1 blocking monoclonal antibodies. The triplet combination of REGO with BRAF/MEK inhibitors appears most active, particularly in the BRAF?V600mut patients.
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene, Stivarga (regorafenib) / Bayer
Journal: Stereotactic Body Radiation Therapy and Concurrent Targeted Therapy for Lung Metastases in Pediatric Sarcoma. (Pubmed Central) - May 27, 2024
With an overall response rate of 92%, SBRT provided a noninvasive effective palliative treatment option with few side effects in this small retrospective study of 7 patients. A larger prospective clinical trial is warranted to evaluate the role of SBRT in the treatment of unresectable metastatic pediatric sarcomas.
- |||||||||| Review, Journal: Biologics for Psoriasis. (Pubmed Central) - May 26, 2024
IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-? inhibitors.
- |||||||||| TQB3616 / Sino Biopharm
Preclinical, Journal: Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor. (Pubmed Central) - May 26, 2024
P3
These differentiated properties, together with excellent GLP safety profile warranted TQB3616 moving to clinic. TQB3616 entered into clinical development in 2019 and currently in phase III clinical trials (NCT05375461, NCT05365178).
- |||||||||| Parsabiv (etelcalcetide) / Amgen
Retrospective data, Journal, Surgery: Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study. (Pubmed Central) - May 25, 2024
This decrease in parathyroidectomies has resulted in an important decrease in complications occurring in cervical surgeries (e.g., perioperative hemorrhage and nerve damage). Conslusions: Despite the fact that these surgical complications cannot be easily compared to the pharmaceutical side effects, the recorded decrease in parathyroidectomies is considered to be notable, especially in cases of relapse where a difficult reoperation would be considered based on previously published guidelines.
- |||||||||| Review, Journal: Insights in Molecular Therapies for Hepatocellular Carcinoma. (Pubmed Central) - May 25, 2024
Established and recommended targeted treatment options that already exist for patients are considered for systemic treatment: atezolizumab/bevacizumab, durvalumab/tremelimumab, sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab. Combination treatment for systemic treatment and local ablative treatment or transarterial chemoembolization and adjuvant and neoadjuvant treatment strategies are under clinical investigation.
- |||||||||| chlorogenic acid / Jiuzhang Biotech
Review, Journal: Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment. (Pubmed Central) - May 25, 2024
It also emphasizes the potential of CGA as a pharmacological adjuvant in cancer treatment with drugs such as 5-fluorouracil, cisplatin, oxaliplatin, doxorubicin, regorafenib, and radiotherapy. By analyzing more than 140 papers from PubMed, Google Scholar, and SciFinder, we hope to find the therapeutic potential of CGA in improving cancer therapy.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: The changing landscape of thyroid eye disease: current clinical advances and future outlook. (Pubmed Central) - May 25, 2024
Long-term safety profiles will require clarification as unintended immunological consequence downstream may become manifest as seen in other diseases. Finally, future novel therapeutics will entail significant expenditure and may lead to a divergence of available treatment modalities between healthcare systems due to funding disparities.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification. (Pubmed Central) - May 24, 2024
However, in humans, while the antisclerostin antibody romosozumab inhibits bone resorption, biochemical parameters of endothelial activation and inflammation are not affected, and the incidence of aneurysms is not increased...Moreover, an increased number of vascular cells converted to osteogenic phenotypes results in increased plasma sclerostin concentrations. Therefore, plasma sclerostin derived from bone limits its importance as a global marker of vascular calcification.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Tecartus (brexucabtagene autoleucel) / Gilead, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Outcomes of patients aged ?26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials. (Pubmed Central) - May 24, 2024
This method of estimating osteoporosis based on MCI classification using DPR images has high sensitivity, especially in patients using AOM, suggesting that this method is useful as a screening test. Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the USA and European Union (EU) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL; aged ?26
- |||||||||| Tavneos (avacopan) / Amgen
Journal: Antineutrophil cytoplasmic antibody-associated vasculitis. (Pubmed Central) - May 24, 2024
Kidney involvement in AAV requires prompt diagnosis and initiation of immunosuppression to prevent irreversible nephron loss. Newer therapeutic targets are on the horizon and offer hope for personalized treatment strategies.
- |||||||||| Review, Journal: Dyslipidaemia management in pregnant patients: a 2024 update. (Pubmed Central) - May 24, 2024
In conclusion, decisions regarding lipid-lowering therapy for pregnant patients should be personalized. Despite the challenges in designing and conducting studies in pregnant women, there is a strong need to establish the safety and efficacy of dyslipidaemia treatment during pregnancy.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Utilization of Romosozumab in Primary Care. (Pubmed Central) - May 24, 2024
Primary care physicians should consider romosozumab for patients at high fracture risk who are intolerant or have not responded to other pharmacological treatment. Further studies are needed to clarify the safety of cardiovascular events.
- |||||||||| AMB-05X / AmMax
Trial termination: A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients (clinicaltrials.gov) - May 23, 2024
P2, N=4, Terminated,
Active, not recruiting --> Terminated; Further enrollment was halted in November 2021, enrolled subjects completed the study. Sponsor stopped further recruitment in this intravenous study to focus on intra-articular route of administration in subjects with tenosynovial giant cell tumor.
- |||||||||| maridebart cafraglutide (AMG 133) / Amgen
Enrollment open: A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - May 23, 2024
P1, N=20, Recruiting,
Sponsor stopped further recruitment in this intravenous study to focus on intra-articular route of administration in subjects with tenosynovial giant cell tumor. Not yet recruiting --> Recruiting
- |||||||||| Lumakras (sotorasib) / Amgen
Journal, IO biomarker: Molecular basis for antibody recognition of multiple drug-peptide/MHC complexes. (Pubmed Central) - May 23, 2024
Deep mutational scanning validated the structures and revealed distinct levels of mutation tolerance by sotorasib- and HLA-binding residues. Together, our structural information and sequence landscape analysis reveal key features for achieving MHC-restricted recognition of multiple hapten-peptide antigens, which will inform the development of next-generation therapeutic antibodies.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Opdivo (nivolumab) / BMS
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP). (Pubmed Central) - May 23, 2024
DRUP persists in improving patients access to off-label targeted or immunotherapy in the Netherlands and beyond. The expansion of DRUP-like clinical trials across Europe provides countless opportunities for broadening the horizon of precision oncology.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Too Much of a Good Thing: Severe Hypercalcemia Presenting with Lethargy and Kidney Failure. (Pubmed Central) - May 23, 2024
Milk alkali syndrome was diagnosed given the history of high-dose calcium / vitamin D supplementation after ruling out other causes of hypercalcemia. After initial treatment with normal saline, furosemide and denosumab, the patient developed severe symptomatic hypocalcemia as a rare adverse effect of denosumab.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Preclinical, Journal: Romosozumab rescues impaired bone mass and strength in a murine model of diabetic kidney disease. (Pubmed Central) - May 23, 2024
These morphological improvements created corresponding increases in cortical bending strength and trabecular compression strength, with STZ-Ad treated mice surpassing vehicle CON mice in all trabecular mechanics measures. These results suggest that Romo retains its efficacy at increasing bone mass and strength in diabetic kidney disease.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
Enrollment closed, Phase classification, Enrollment change, Metastases: PALVEN: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (clinicaltrials.gov) - May 22, 2024
P1, N=17, Active, not recruiting,
These results suggest that Romo retains its efficacy at increasing bone mass and strength in diabetic kidney disease. Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | N=36 --> 17
- |||||||||| Review, Journal: Navigating Biologic Therapies in Elderly Asthma. (Pubmed Central) - May 22, 2024
In summary, this review navigates the current landscape of biologic therapies for elderly asthmatics, offering valuable insights for various stakeholders, including researchers, healthcare providers, and policymakers, to advance asthma care in this vulnerable population. We propose that future research should concentrate on tailored, evidence-based approaches to address the undertreatment of elderly asthma patients.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Clinical, Journal, Adverse events: Re: Shah et (Pubmed Central) - May 22, 2024
We propose that future research should concentrate on tailored, evidence-based approaches to address the undertreatment of elderly asthma patients. No abstract available
- |||||||||| ONX 0914 / Protalex, Amgen
Preclinical, Journal: Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice. (Pubmed Central) - May 22, 2024
Concomitant with the reduction in white adipose tissue mass upon ONX-0914 treatment, we observed improvements in markers of metabolic syndrome, including lowered plasma triglyceride levels, insulin levels, and fasting blood glucose. We propose that immunoproteasomal inhibition reduces 3 major causes underlying cardiovascular disease, dyslipidemia, metabolic syndrome, and inflammation and is a new target in drug development for atherosclerosis treatment.
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Major Pancreatic Resection Increases Bone Mineral Density Loss, Osteoporosis, and Fractures. (Pubmed Central) - May 22, 2024
After pancreatic resection, patients are at higher risk for BMD loss and subsequent fractures. As the cohort of pancreatic resection survivorship grows, attention will need to be paid to focused prevention efforts to reduce BMD loss, osteoporosis, and fractures in these vulnerable patients, with specific attention to the pancreatic cancer population.
|
